In early 2021, ADMA Biologics was trading poorly at low single-digit levels per share, despite owning nine plasma collection centers and a manufacturing facility in Boca Raton, Florida. The enterprise value at that time closely matched the standalone asset value of these secured plasma centers, suggesting minimal downside risk. Insider buying by executives and directors totaled over $2 million in open-market purchases during 2021–2022, signaling confidence in management’s view that the business was significantly undervalued.

ADMA Biologics delivered compound annual revenue growth exceeding 25% between 2021 and 2024, driven primarily by increased uptake of its hyperimmune products. In 2024, the company reported approximately $460 million in revenue, up from $350 million in the prior year. This growth trajectory has been supported by expanded capacity at the Boca Raton plant, which increased monthly production by over 30% following a second fill-finish line coming online in mid-2023.

In its preliminary update for full-year 2025, ADMA projected revenues of $510 million to $511 million, surpassing the consensus analyst estimate of $495 million. This performance reflects robust demand for Asceniv, the proprietary immunoglobulin indicated for primary immune deficiency disorders. Gross margin for the period is expected to expand to the mid-50% range, up from 52% in 2024, driven by operational efficiencies and favorable plasma procurement costs.

Building on strong Asceniv demand, management has increased its 2026 outlook, calling for revenue growth in the high teens and adjusted EBITDA margins approaching 25%. The company plans to optimize its plasma sourcing network and implement cost synergies from its recent acquisition of two additional donor centers in the Midwest. A shareholder rights plan was also adopted in late 2025 to protect long-term value against unsolicited takeover attempts, underscoring the board’s commitment to executing its strategic plan.